Companies › Radiopharm Theranostics
4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RAD101 18F-labeled fibroblast activation protein inhibitor (FAPI) PET imaging agent | – | Phase 2 | Brain Metastases From Solid Tumors | – |
| 177Lu-BetaBart Lutetium-177 labeled anti-B7-H3 monoclonal antibody | B7H3 | Phase 1 | Castration-Resistant Prostate Cancer (CRPC) | Dec 2027 |
| 161Tb-RAD402 Radiolabeled anti-KLK3 monoclonal antibody targeting free prostate-specific antigen | KLK3 | Phase 1 | Castration-resistant Prostate Cancer | Nov 2028 |
| RAD301 ([68Ga]-RAD301) Radiopharmaceutical diagnostic imaging agent | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06777433 | RAD101 | Phase 2 | Brain Metastases From Solid Tumors | Oncology | Apr 2026 |
| NCT05799274 | RAD301 ([68Ga]-RAD301) | Phase 1 | Healthy Volunteers | Oncology | Sep 2026 |
| NCT07189871 | 177Lu-BetaBart | Phase 1 | Castration-Resistant Prostate Cancer (CRPC) | Oncology | Dec 2027 |
| NCT07259213 | 161Tb-RAD402 | Phase 1 | Castration-resistant Prostate Cancer | Oncology | Nov 2028 |
Cash of $29m on 2025-06-30; operating cash outflow about $37m a year; runway about 10 months at that burn, to Apr 2026
Innate Pharma Processa Pharmaceuticals Moleculin Biotech Tyra Biosciences Cellectar Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.